import { DrugLabel } from "../../../types/drug";

export const mourjaroData: DrugLabel = {
  "drugName": "Mounjaro",
  "setId": "d2d7da5d-ad07-4228-955f-cf7e355c8cc0",
  "slug": "mounjaro-d2d7da5",
  "labeler": "Eli Lilly and Company",
  "label": {
    "boxedWarning": "<div class=\"Warning\" id=\"boxed-warning\"><div><h2 class=\"Warning\"><span class=\"Bold\">WARNING: RISK OF THYROID C-CELL TUMORS</span></h2><h2 class=\"Warning\"><span class=\"Bold Italics\">See full prescribing information for complete boxed warning.</span></h2><ul class=\"Disc\"><li><span class=\"Bold\">Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined (<a href=\"#s10\">5.1</a>, <a href=\"#s72\">13.1</a>).</span></li><li><span class=\"Bold\">MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors (<a href=\"#s8\">4</a>, <a href=\"#s10\">5.1</a>).</span></li></ul></div></div>",
    "genericName": "tirzepatide",
    "labelerName": "Eli Lilly and Company",
    "productType": "HUMAN PRESCRIPTION DRUG LABEL",
    "effectiveTime": "20250114",
    "title": "MOUNJARO",
    "indicationsAndUsage": "<section class=\"Section\" data-sectioncode=\"34067-9\"><a name=\"s2\"></a><a name=\"section-1\"></a><p></p><h1>1 INDICATIONS AND USAGE</h1><p class=\"First\">MOUNJARO<span class=\"Sup\">®</span> is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s3\"></a><a name=\"section-1.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Limitations of Use</span></p><ul class=\"Disc\"><li>MOUNJARO has not been studied in patients with a history of pancreatitis <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s11\">5.2</a>)]</span>.</li><li>MOUNJARO is not indicated for use in patients with type 1 diabetes mellitus.</li></ul></div></section>",
    "dosageAndAdministration": "<section class=\"Section\" data-sectioncode=\"34068-7\"><a name=\"s4\"></a><a name=\"section-2\"></a><p></p><h1>2 DOSAGE AND ADMINISTRATION</h1><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s5\"></a><a name=\"section-2.1\"></a><p></p><h2>2.1 Dosage</h2><ul class=\"Disc\"><li>The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s15\">5.6</a>) and Adverse Reactions (<a href=\"#s19\">6.1</a>)]</span>. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control.</li><li>After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.</li><li>If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.</li><li>The maximum dosage of MOUNJARO is 15 mg injected subcutaneously once weekly.</li><li>If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.</li></ul></div></section>",
    "dosageFormsAndStrengths": "Injectable dosage forms with multiple strengths",
    "warningsAndPrecautions": "Thyroid C-cell tumors, pancreatitis, hypersensitivity reactions, gastrointestinal adverse reactions",
    "adverseReactions": "Most common adverse reactions include nausea, diarrhea, decreased appetite, vomiting, constipation",
    "clinicalPharmacology": "<section class=\"Section\" data-sectioncode=\"34090-1\"><a name=\"s52\"></a><a name=\"section-11\"></a><p></p><h1>12 CLINICAL PHARMACOLOGY</h1><div class=\"Section\" data-sectioncode=\"43679-0\"><a name=\"s53\"></a><a name=\"section-11.1\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\"First\">Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It is an amino-acid sequence including a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1.</p><p>Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.</p></div></section>",
    "clinicalStudies": "<section class=\"Section\" data-sectioncode=\"34092-7\"><a name=\"s73\"></a><a name=\"section-13\"></a><p></p><h1>14 CLINICAL STUDIES</h1><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s74\"></a><a name=\"section-13.1\"></a><p></p><h2>14.1 Overview of Clinical Studies</h2><p class=\"First\">The effectiveness of MOUNJARO as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus was established in five trials.</p></div></section>",
    "howSupplied": "Available in multiple vial and pen presentations with proper storage requirements",
    "useInSpecificPopulations": "Not established in pediatric patients. No dosage adjustment needed for renal or hepatic impairment. Pregnancy and lactation considerations apply.",
    "description": "<section class=\"Section\" data-sectioncode=\"34089-3\"><a name=\"s51\"></a><a name=\"section-10\"></a><p></p><h1>11 DESCRIPTION</h1><p class=\"First\">MOUNJARO (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a once weekly GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker.</p></section>",
    "nonClinicalToxicology": "Animal studies showing thyroid C-cell tumors in rats",
    "instructionsForUse": "Detailed injection instructions for subcutaneous administration with proper needle disposal guidelines",
    "mechanismOfAction": "<section class=\"Section\" data-sectioncode=\"43679-0\"><a name=\"s53\"></a><a name=\"section-11.1\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\"First\">Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It is an amino-acid sequence including a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1.</p><p>Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.</p></section>",
    "contraindications": "<section class=\"Section\" data-sectioncode=\"34070-3\"><a name=\"s8\"></a><a name=\"section-4\"></a><p></p><h1>4 CONTRAINDICATIONS</h1><p class=\"First\">MOUNJARO is contraindicated in patients with:</p><ul class=\"Disc\"><li>A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s10\">5.1</a>)]</span>.</li><li>Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with MOUNJARO <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s13\">5.4</a>)]</span>.</li></ul></section>",
    "highlights": {
      "dosageAndAdministration": "<div><ul class=\"Disc\"><li>The recommended starting dosage is 2.5 mg injected subcutaneously once weekly (<a href=\"#s5\">2.1</a>)</li><li>After 4 weeks, increase to 5 mg injected subcutaneously once weekly (<a href=\"#s5\">2.1</a>)</li><li>If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.</li><li>The maximum dosage is 15 mg subcutaneously once weekly (<a href=\"#s5\">2.1</a>).</li><li>Administer once weekly at any time of day, with or without meals. (<a href=\"#s6\">2.2</a>)</li><li>Inject subcutaneously in the abdomen, thigh, or upper arm.</li></ul></div>"
    }
  }
};

export const relatedDrugs = [
  {
    slug: "ozempic",
    name: "Ozempic",
    genericName: "semaglutide",
    therapeuticClass: "GLP-1 receptor agonist"
  },
  {
    slug: "trulicity",
    name: "Trulicity",
    genericName: "dulaglutide",
    therapeuticClass: "GLP-1 receptor agonist"
  },
  {
    slug: "rybelsus",
    name: "Rybelsus",
    genericName: "semaglutide",
    therapeuticClass: "Oral GLP-1 receptor agonist"
  }
];

// Export drugData for the generation script
export const drugData = {
  drugName: mourjaroData.drugName,
  genericName: mourjaroData.label.genericName,
  slug: mourjaroData.slug,
  setId: mourjaroData.setId,
  activeIngredient: mourjaroData.label.genericName,
  therapeuticClass: "GLP-1/GIP Receptor Agonist",
  manufacturer: mourjaroData.labeler,
  boxedWarning: mourjaroData.label.boxedWarning,
  indicationsAndUsage: mourjaroData.label.indicationsAndUsage,
  dosageAndAdministration: mourjaroData.label.dosageAndAdministration,
  contraindications: mourjaroData.label.contraindications,
  warnings: mourjaroData.label.warningsAndPrecautions,
  adverseReactions: mourjaroData.label.adverseReactions,
  drugInteractions: "MOUNJARO delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.",
  clinicalPharmacology: mourjaroData.label.clinicalPharmacology,
  clinicalStudies: mourjaroData.label.clinicalStudies,
  howSupplied: mourjaroData.label.howSupplied,
  patientCounseling: "Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).",
  description: mourjaroData.label.description,
  overdosage: "In the event of overdosage, contact Poison Control for latest recommendations. Based on the pharmacological actions of tirzepatide, an overdose may result in gastrointestinal adverse reactions and hypoglycemia.",
  nonClinicalToxicology: mourjaroData.label.nonClinicalToxicology,
  principalDisplayPanel: "NDC 0002-1434-80\nMOUNJARO™\n(tirzepatide) injection\n2.5 mg/0.5 mL\nFor subcutaneous use only\nSingle-Dose Pen\nRx only"
};
